Related Experiment Video
Updated: Jun 19, 2026
08:31
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Patient Preferences for Treatment in Relapsed/Refractory Acute Leukemia: A Multinational Discrete Choice Experiment.
Samantha Nier1, Hannah Hussain2, Jake Hitch2,3
1Acute Leukemia Advocates Network, Bern, Switzerland.
Patient Preference and Adherence
|June 18, 2026
Summary
Patients with acute leukemia (AL) prioritize treatment efficacy, but also value quality of life and convenience. Understanding these preferences is key for personalized cancer care decisions.
Area of Science:
- Oncology
- Health Economics
- Behavioral Science
Background:
- Acute leukemia (AL) is a rapidly progressing cancer requiring intensive treatment.
- Treatment decisions for refractory or relapsed AL involve complex trade-offs between efficacy, toxicity, and quality of life.
- Limited evidence exists on how AL patients value specific treatment features.
Purpose of the Study:
- To quantify treatment preferences among adults with acute leukemia (AL).
- To identify key attributes influencing treatment decisions in AL.
- To explore heterogeneity in patient preferences for AL therapies.
Main Methods:
- A web-based discrete choice experiment (DCE) was conducted with 267 adult AL patients across the UK, USA, France, Germany, and Italy.
- Hypothetical treatment profiles were presented, varying by chance of response, duration of response, quality of life during treatment and response, and mode of administration.
- Data were analyzed using mixed logit and latent class models to estimate relative attribute importance (RAI) and preference classes.
Main Results:
- The chance of response was the most influential attribute (RAI=62%), followed by quality of life during response (14%) and duration of response (9%).
- Three distinct preference classes were identified: efficacy-focused (47%), convenience- and efficacy-focused (21%), and balanced decision-makers (32%).
- Respondents from the USA showed a higher likelihood of belonging to the convenience- and efficacy-focused group.
Conclusions:
- Acute leukemia patients prioritize treatment efficacy but also value quality of life and convenience.
- Treatment decisions in AL are multifaceted and influenced by context.
- Incorporating patient preferences is crucial for person-centered care in AL clinical development and health technology assessment.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:15Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...